Vaxart gets $29M BARDA funding to advance COVID pill vaccine data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
June 25, 2026 8:00 AM EDTLatest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort
Funding to Advance Data Analysis from More Than 5,000 Trial Participants
Ahead of Key Trial Results
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (Vaxart or the Company), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology... More
